Tarsus to Acquire Alkeus in Up to $800 Million Deal for Rare Eye Disease Drug
Tarsus to acquire Alkeus for up to $800M, adding late-stage oral therapy for Stargardt disease – a rare eye disorder with no approved treatments.
/ 3 items
#TARS↓
Short Seller Culper Attacks Tarsus Pharmaceuticals Over XDEMVY Market Size
Culper Research argues Tarsus is significantly overvalued, disputing the addressable market for its Demodex blepharitis drug XDEMVY.
Mizuho Starts Coverage on Tarsus Pharmaceuticals With Bullish $100 Target
Mizuho initiates coverage on Tarsus Pharmaceuticals with an Outperform rating and a $100 price target, citing strong prospects for Xdemvy and projected peak sales above $2B.